<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert C Lowe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher D Anderson, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Although these cancers are rare in the United States, they are highly lethal because most are locally advanced at presentation.</p><p>The epidemiology, pathology, pathogenesis, and classification of cholangiocarcinoma will be discussed here. Clinical manifestations, diagnosis, and treatment are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2467.html" rel="external">"Adjuvant and neoadjuvant therapy for localized cholangiocarcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2497.html" rel="external">"Treatment options for locally advanced, unresectable, but nonmetastatic cholangiocarcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma"</a>.)</p><p>Cancers of the gallbladder and ampulla of Vater are discussed as separate disease processes, although these structures are part of the biliary drainage system. (See  <a class="medical medical_review" href="/z/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/655.html" rel="external">"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANATOMY, TUMOR CLASSIFICATION, AND STAGING</span><span class="headingEndMark"> — </span>Biliary tract cancers were traditionally divided according to their anatomical primary site into cancers of the gallbladder, the extrahepatic ducts, and the ampulla of Vater, while intrahepatic tumors of the bile system were classified as primary liver cancers. More recently, the term cholangiocarcinoma has been used to refer to bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of the gallbladder or ampulla of Vater.</p><p>Anatomically, intrahepatic cholangiocarcinomas originate from small intrahepatic ductules (termed peripheral cholangiocarcinomas) or large intrahepatic ducts proximal to the bifurcation of the right and left hepatic ducts. The extrahepatic bile ducts are divided into perihilar (including the confluence itself) and distal segments, with the transition occurring at the point where the common bile duct lies posterior to the duodenum, proximal to the insertion of the cystic duct into the common bile duct  (<a class="graphic graphic_figure graphicRef52489" href="/z/d/graphic/52489.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>].</p><p>In general, perihilar disease represents approximately 50 percent; distal disease, 40 percent; and intrahepatic disease, less than 10 percent of cholangiocarcinoma cases [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Bismuth-Corlette classification for perihilar tumors</span><span class="headingEndMark"> — </span>Cancers arising in the perihilar region have been further classified according to their patterns of involvement of the hepatic ducts (the Bismuth-Corlette classification)  (<a class="graphic graphic_figure graphicRef75886" href="/z/d/graphic/75886.html" rel="external">figure 2</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumors below the confluence of the left and right hepatic ducts (Type I)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors reaching the confluence (Type II)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors occluding the common hepatic duct and either the right or left hepatic duct (Types IIIa and IIIb, respectively)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors that are multicentric, or that involve the confluence and both the right or left hepatic duct (Type IV)</p><p></p><p>Bile duct tumors that involve the common hepatic duct bifurcation are referred to as Klatskin tumors or hilar cholangiocarcinoma regardless of whether they arise from the intrahepatic or extrahepatic portion of the biliary tree [<a href="#rid3">3</a>]. Perihilar tumors account for approximately 50 percent of all cholangiocarcinomas, while approximately 40 percent are distal extrahepatic tumors, and 10 percent or fewer are intrahepatic [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h2">TNM staging classifications</span><span class="headingEndMark"> — </span>The newest version of the combined American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) cancer staging manual provides separate staging systems for cancers of the perihilar  (<a class="graphic graphic_table graphicRef110944" href="/z/d/graphic/110944.html" rel="external">table 1</a>), distal  (<a class="graphic graphic_table graphicRef110943" href="/z/d/graphic/110943.html" rel="external">table 2</a>), and intrahepatic bile ducts  (<a class="graphic graphic_table graphicRef110945" href="/z/d/graphic/110945.html" rel="external">table 3</a>), which all differ in their definitions of tumor (T) stage and in their prognostic stage groupings. The rare combined hepatocellular and cholangiocarcinomas (mixed hepatocholangiocarcinomas) are included in the intrahepatic bile duct classification. (See <a class="local">'Combined hepatocellular-cholangiocarcinoma'</a> below.)</p><p>There are major changes for all three sites compared with the seventh (2010) edition of the AJCC staging manual:</p><p class="bulletIndent1"><span class="glyph">●</span>For distal bile duct tumors, regional nodal (N) staging has been expanded according to the number of involved nodes, rather than just their presence or absence, and T staging now depends on the depth, in millimeters, of tumor invasion into the bile duct wall  (<a class="graphic graphic_table graphicRef110943" href="/z/d/graphic/110943.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For perihilar tumors, the N category has been reclassified based upon the number of involved lymph nodes, instead of the location of the involved nodes, and Bismuth-Corlette type IV tumors have been removed from the T4 category; in addition, the prognostic stage groups have been changed  (<a class="graphic graphic_table graphicRef110944" href="/z/d/graphic/110944.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For intrahepatic tumors, there are no changes to the N categories (nodal involvement [N1] versus no nodal involvement [N0]), but the T1 category has been split to reflect the prognostic importance of tumor size, and the T2 category is modified to reflect the equivalent prognostic value of vascular invasion and tumor multifocality  (<a class="graphic graphic_table graphicRef110945" href="/z/d/graphic/110945.html" rel="external">table 3</a>) [<a href="#rid5">5</a>]. </p><p></p><p>These prominent changes in the staging classification of bile duct cancers over time have improved the prognostic stratification of the Tumor, Node, Metastasis (TNM) staging system. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Stratification of survival according to the newest 2017 T stage designations for distal cholangiocarcinomas (which are now based upon depth of tumor invasion rather than what structures were invaded) is provided in the figure  (<a class="graphic graphic_figure graphicRef111032" href="/z/d/graphic/111032.html" rel="external">figure 3</a>) [<a href="#rid4">4,6</a>], while stratified survival according to N category is depicted in this figure  (<a class="graphic graphic_figure graphicRef111045" href="/z/d/graphic/111045.html" rel="external">figure 4</a>) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Survival stratified according to the new prognostic stage groupings for tumors of the perihilar bile ducts is provided in a separate figure  (<a class="graphic graphic_figure graphicRef111047" href="/z/d/graphic/111047.html" rel="external">figure 5</a>) [<a href="#rid1">1</a>], as is survival stratified according to T stage for intrahepatic cholangiocarcinomas  (<a class="graphic graphic_figure graphicRef111048" href="/z/d/graphic/111048.html" rel="external">figure 6</a>) [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A comparison of five-year survival stratified by stage groupings according to the 2010 and 2017 editions of the AJCC staging classification for intrahepatic cholangiocarcinoma in a series of 1154 patients undergoing potentially curative resection for intrahepatic cholangiocarcinoma at 14 major hepatobiliary centers is provided in the table  (<a class="graphic graphic_table graphicRef113799" href="/z/d/graphic/113799.html" rel="external">table 4</a>) [<a href="#rid7">7</a>].</p><p></p><p>The continued evolution of the staging classification for bile duct cancers at all sites has obvious implications for interpretation and comparison of outcomes from trials and retrospective series that use older TNM staging criteria.</p><p>A criticism of the TNM staging system is that vessel invasion, as detected on the final pathology specimen, affects T stage category, but it is not used to assess local resectability. As such, the stage groupings do not serve as a guide for choosing local therapy. A modification to the tumor staging system for perihilar tumors has been proposed that incorporates the Bismuth-Corlette classification and a more detailed assessment of major vascular invasion, as well as liver remnant volume and underlying liver disease [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cholangiocarcinomas account for approximately 3 percent of all gastrointestinal malignancies, with a prevalence in autopsy studies of 0.01 to 0.46 percent [<a href="#rid9">9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incidence data from the American Cancer Society are difficult to interpret because intrahepatic bile duct cancers have been included with primary liver cancers, while extrahepatic biliary cancers are in a separate category that includes gallbladder cancer:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the United States, approximately 41,000 cases of primary liver and intrahepatic bile duct cancers are diagnosed annually [<a href="#rid10">10</a>]. Data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program suggest that approximately 15 percent of these are intrahepatic cholangiocarcinomas [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Approximately 12,000 cases of extrahepatic biliary tract cancers are diagnosed annually in the United States [<a href="#rid10">10</a>], two-thirds of which are gallbladder cancers. The remainder, approximately 3000 cases per year, are extrahepatic cholangiocarcinomas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data from an analysis of the United States SEER database from 2001 to 2015 suggest an incidence of 1.26 cases of cholangiocarcinoma per 100,000 people per year, and that two-thirds of cases are intrahepatic [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internationally</strong> – Internationally, the incidence of cholangiocarcinoma varies significantly. While the incidence is low in high-income countries (from 0.35 to 2 cases per 100,000 population per year), in endemic regions of Thailand and China, the incidence is up to 40-fold higher [<a href="#rid14">14-16</a>].</p><p></p><p>Globally, the burden of gallbladder and other biliary tract cancers has risen over the last 30 years [<a href="#rid17">17</a>]. In particular, the incidence and mortality of intrahepatic cholangiocarcinoma has been rising over the past four decades in most countries [<a href="#rid11">11,12,14,18-25</a>] (although not Denmark [<a href="#rid18">18</a>]). Rates of extrahepatic cholangiocarcinoma had been declining internationally up to approximately the year 2000 [<a href="#rid11">11,12,18-23</a>], but more recent reports suggest an increased incidence over the last 20 years [<a href="#rid24">24</a>].</p><p>Some of these apparent differences may be due to changes in ICD (International Classification of Disease) classification [<a href="#rid26">26</a>]. Klatskin tumors often invade the liver by the time of presentation which may result in some extrahepatic cholangiocarcinomas misclassified as intrahepatic in origin, thereby contributing to possible underestimation of the incidence of extrahepatic cholangiocarcinomas. In addition, at least some of the increase in intrahepatic cholangiocarcinomas may be attributable to new diagnostic methods for obstructive jaundice that identify biliary malignancies that previously might have gone undiagnosed [<a href="#rid27">27</a>]. However, the rising rates of intrahepatic cholangiocarcinoma have not been associated with an increase in the proportion of early stage or smaller size lesions [<a href="#rid12">12</a>]. Furthermore, incidence rates do not seem to be plateauing.</p><p>Other studies suggest that the increasing incidence of cholangiocarcinoma may be related to a concomitant increase in certain risk factors such as cirrhosis, alcoholic liver disease, and hepatitis C virus infection [<a href="#rid24">24,28</a>]. (See <a class="local">'Risk factors'</a> below.)</p><p>As a general rule, the incidence of biliary tract cancers increases with age [<a href="#rid29">29</a>]; the typical patient with cholangiocarcinoma is between 50 and 70 years of age. However, patients with cholangiocarcinomas arising in the setting of primary sclerosing cholangitis (PSC) and those with choledochal cysts present nearly two decades earlier [<a href="#rid9">9,30</a>]. In contrast to gallbladder cancer, where female gender predominates, the incidence of cholangiocarcinoma is slightly higher in men [<a href="#rid29">29</a>]. This probably reflects the higher incidence of PSC in men [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/659.html" rel="external">"Primary sclerosing cholangitis: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>A number of risk factors for cholangiocarcinoma have been recognized, although a specific risk factor cannot be identified for many patients [<a href="#rid32">32</a>]. In the United States and Europe, the main risk factors are primary sclerosing cholangitis (PSC) and fibropolycystic liver disease (eg, choledochal cysts). There is a clear and strong association between chronic intrahepatic stone disease (hepatolithiasis, also called recurrent pyogenic cholangitis) and cholangiocarcinoma [<a href="#rid33">33</a>]. Chronic liver disease (cirrhosis and viral infection) is now recognized as a risk factor, particularly for intrahepatic cholangiocarcinoma [<a href="#rid33">33</a>]. (See <a class="local">'Primary hepatobiliary disease'</a> below.)</p><p>In certain regions (eg, Thailand) chronic infection with liver fluke is the driving risk factor. (See <a class="local">'Parasitic infection'</a> below.)</p><p>Finally, at least four genetic conditions, Lynch syndrome, <em>BRCA</em>-associated protein-1 (BAP1) tumor predisposition syndrome, cystic fibrosis, and biliary papillomatosis, appear to increase the risk for cholangiocarcinoma. (See <a class="local">'Genetic disorders'</a> below.)</p><p class="headingAnchor" id="H2935613630"><span class="h2">Primary hepatobiliary disease</span></p><p class="headingAnchor" id="H8"><span class="h3">Primary sclerosing cholangitis</span><span class="headingEndMark"> — </span>PSC is an inflammatory disorder of the biliary tree that leads to fibrosis and stricturing of the intrahepatic and/or extrahepatic bile ducts. PSC is strongly associated with inflammatory bowel disease, notably ulcerative colitis (UC); approximately 40 to 50 percent of patients have symptomatic colitis, while the incidence of colitis is around 90 percent in patients with PSC [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/659.html" rel="external">"Primary sclerosing cholangitis: Epidemiology and pathogenesis"</a>.)</p><p>There is a well-established association between PSC and cholangiocarcinoma, especially perihilar disease. Nearly 30 percent of cholangiocarcinomas are diagnosed in patients with PSC, with or without UC. The annual incidence of cholangiocarcinoma in patients with PSC has been estimated to be between 0.6 and 1.5 percent per year, with a lifetime risk of 5 to 15 percent [<a href="#rid35">35-41</a>]. However, the incidence is much higher (30 percent or more) in autopsy series [<a href="#rid42">42</a>]. Cholangiocarcinomas develop at a significantly younger age (between the ages of 30 and 50) in patients with PSC than in those without this condition. It is also more difficult to diagnose because of the diffusely abnormal biliary tree [<a href="#rid43">43</a>]. Over one-third of cases are diagnosed within two years of the initial diagnosis of PSC, and the risk appears unrelated to the duration of the inflammatory disease [<a href="#rid30">30,37,42</a>]. However, a population-based patient series from the Netherlands has questioned previous notions that late presentation of cholangiocarcinoma is a rare event, reporting that 37 percent of cholangiocarcinomas present more than 10 years after the diagnosis of PSC [<a href="#rid44">44</a>]. Thus, clinical and biochemical deterioration at any point in the disease course should prompt evaluation for a potentially malignant cause. (See  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma", section on 'When to consider cholangiocarcinoma'</a>.)</p><p>The reason why patients with PSC develop cholangiocarcinoma is not well understood, although there have been several observations.</p><p class="bulletIndent1"><span class="glyph">●</span>One case-control study attempted to identify specific risk factors by comparing 20 patients with PSC and hepatobiliary carcinoma (17 of whom had cholangiocarcinoma) with 20 age- and sex-matched patients with PSC without cancer [<a href="#rid37">37</a>]. No clinical or biochemical risk factors for the development of cancer could be identified in the year before cancer diagnosis. However, the number of patients who smoked or were former smokers was significantly higher in the cancer group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol consumption has been suggested to be a risk factor for the development of cholangiocarcinoma in patients with PSC [<a href="#rid37">37</a>]. One study compared 26 patients with PSC and cholangiocarcinoma with 87 patients with PSC but without tumors [<a href="#rid45">45</a>]. Only alcohol consumption was significantly associated with the development of cancer (odds ratio [OR] of 2.95; 95% CI 1.04-8.3). However, these authors could not test for a dose-response relationship due to inadequate data, and they could not confirm the link between smoking and cholangiocarcinoma in PSC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain genetic polymorphisms have been implicated as risk factors for cholangiocarcinoma in PSC [<a href="#rid46">46</a>].</p><p></p><p>The development of cholangiocarcinoma is heralded by rapid clinical deterioration with jaundice, weight loss, and abdominal discomfort; tumors are often detected at an advanced stage. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma", section on 'When to consider cholangiocarcinoma'</a>.) </p><p>Issues related to cancer screening, typically by serial assay of the tumor marker carbohydrate antigen (CA) 19-9, in patients with PSC are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma", section on 'CA 19-9'</a> and  <a class="medical medical_review" href="/z/d/html/661.html" rel="external">"Primary sclerosing cholangitis in adults: Management", section on 'Cancer screening'</a>.) </p><p class="headingAnchor" id="H9"><span class="h3">Fibropolycystic liver disease</span><span class="headingEndMark"> — </span>Congenital abnormalities of the biliary tree (Caroli syndrome, congenital hepatic fibrosis, choledochal cysts) carry an approximately 15 percent risk of malignant change in the adult years (average age at diagnosis 34) [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/z/d/html/651.html" rel="external">"Biliary cysts"</a> and  <a class="medical medical_review" href="/z/d/html/650.html" rel="external">"Caroli disease"</a>.)</p><p>Choledochal cysts are congenital cystic dilatations of the bile ducts, while Caroli disease is a variant of choledochal cyst disease that is characterized by multiple cystic dilations of the intrahepatic biliary ducts [<a href="#rid50">50</a>]. The overall incidence of cholangiocarcinoma in patients with untreated cysts is as high as 28 percent [<a href="#rid48">48,49</a>].</p><p>Although the mechanism underlying carcinogenesis in these patients is unclear, it could be related to biliary stasis, chronic inflammation from reflux of pancreatic juice, or abnormalities in bile salt transporter proteins that result in unstable bile content, or deconjugation of carcinogens that were previously conjugated in the liver [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Cholelithiasis, cholecystitis, and hepatolithiasis</span><span class="headingEndMark"> — </span>While cholelithiasis is a well-described strong risk factor for gallbladder cancer, the association between gallstones and cholangiocarcinoma is less well established. However, at least four epidemiologic studies note an increased risk for cholangiocarcinoma among patients with symptomatic gallstone disease or cholecystitis, but of a lower magnitude than for gallbladder cancer [<a href="#rid51">51-54</a>]. (See  <a class="medical medical_review" href="/z/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis", section on 'Gallstone disease'</a>.)</p><p>There is a clear and strong association between chronic intrahepatic stone disease (hepatolithiasis, also called recurrent pyogenic cholangitis) and cholangiocarcinoma [<a href="#rid55">55-62</a>]. Stone disease affecting only the intrahepatic bile ducts is exceedingly rare in the West but is endemic in certain parts of Southeast Asia. In Taiwan, 50 to 70 percent of patients undergoing resection for cholangiocarcinoma have associated hepatolithiasis [<a href="#rid57">57,58</a>], while in Japan, the incidence is much lower (6 to 18 percent) [<a href="#rid59">59-61</a>]. (See  <a class="medical medical_review" href="/z/d/html/652.html" rel="external">"Recurrent pyogenic cholangitis"</a>.)</p><p>The etiology of hepatolithiasis is not known, but congenital ductal abnormalities, diet, and chronic inflammation from bacterial or parasitic infections have all been implicated. The calculi are usually composed of calcium bilirubinate (brown pigment stones) rather than cholesterol. The biliary stones are thought to cause bile stasis, predisposing to recurrent bacterial infections and chronic inflammation.</p><p>It may be difficult to identify cholangiocarcinomas arising as a complication of hepatolithiasis. However, the diagnosis should be suspected in a patient over the age of 40 who has a long history of hepatolithiasis, weight loss, elevated serum alkaline phosphatase, a serum carcinoembryonic antigen (CEA) level above 4.2 ng/mL, and hepatolithiasis in either the right or both lobes of the liver [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Chronic liver disease</span><span class="headingEndMark"> — </span>Hepatitis B virus (HBV) and hepatitis C virus (HCV), as well as liver cirrhosis regardless of etiology, have been examined as risk factors for intrahepatic cholangiocarcinoma [<a href="#rid28">28,62,64-66</a>].</p><p class="headingAnchor" id="H15"><span class="h4">Viral hepatitis</span><span class="headingEndMark"> — </span>An association between HCV infection and cholangiocarcinoma was initially suggested in 1991 [<a href="#rid67">67</a>]. Since then, several reports have noted a higher than expected rate of HCV-associated cirrhosis in patients with cholangiocarcinoma, although the risk is much lower than for hepatocellular cancer [<a href="#rid12">12,28,65,68-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective case control study from Japan reported the risk of developing cholangiocarcinoma in patients with cirrhosis related to HCV was 3.5 percent at 10 years [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A large cohort study in the United States found a significant association between intrahepatic cholangiocarcinoma and HCV after adjustment for potential confounders, including cirrhosis (adjusted relative risk [RR] 2.55, 95% CI 1.31-4.95) [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a large cohort study of older United States adults derived from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database found that HCV positivity was associated with a significant increase in the risk of both extrahepatic (adjusted odds ratio [aOR] 1.90, 95% CI 1.41-2.57) and intrahepatic (aOR 3.40, 95% CI 2.52-4.58) cholangiocarcinomas [<a href="#rid78">78</a>]. </p><p></p><p>An association between HBV infection and cholangiocarcinoma has also been suggested, although the data are less compelling than for HCV [<a href="#rid62">62,74,79,80</a>].</p><p class="headingAnchor" id="H16"><span class="h4">Nonviral chronic liver disease</span><span class="headingEndMark"> — </span>As with hepatocellular carcinoma, chronic liver disease of nonviral etiology also appears to be associated with intrahepatic cholangiocarcinoma [<a href="#rid12">12,28,62,64-66,68,81</a>]. In a case-control study, risk factors that were significantly more prevalent among patients with intrahepatic cholangiocarcinoma included nonspecific cirrhosis (aOR 27.2) and alcoholic liver disease (aOR 7.4) [<a href="#rid28">28</a>]. A Danish cohort study that followed 11,605 persons with cirrhosis from any cause for an average of approximately six years found a significant 10-fold higher risk for intrahepatic cholangiocarcinoma among these patients compared with the general population [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1170375544"><span class="h4">Precursor (intraductal) lesions</span><span class="headingEndMark"> — </span>There are three known precursors to invasive cholangiocarcinoma: intraductal papillary neoplasm of the bile ducts  (<a class="graphic graphic_picture graphicRef97392" href="/z/d/graphic/97392.html" rel="external">picture 1</a>) [<a href="#rid82">82,83</a>], the rare intraductal tubulopapillary neoplasm of the bile ducts  (<a class="graphic graphic_picture graphicRef114106" href="/z/d/graphic/114106.html" rel="external">picture 2</a>) [<a href="#rid83">83,84</a>], and the much more common biliary intraepithelial neoplasia  (<a class="graphic graphic_picture graphicRef98058" href="/z/d/graphic/98058.html" rel="external">picture 3</a>) [<a href="#rid85">85,86</a>]. (See <a class="local">'Papillary'</a> below and  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Biliary intraepithelial neoplasia'</a> and  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Intraductal papillary neoplasm of bile duct'</a> and  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Intraductal tubulopapillary neoplasm of bile duct'</a>.)</p><p class="headingAnchor" id="H647555"><span class="h2">Genetic disorders</span><span class="headingEndMark"> — </span>At least four genetic disorders are associated with an increased risk of cholangiocarcinoma: Lynch syndrome (hereditary nonpolyposis colorectal cancer), BAP1 tumor predisposition syndrome, cystic fibrosis, and a rare inherited disorder called multiple biliary papillomatosis. </p><p class="headingAnchor" id="H1858534116"><span class="h3">Lynch syndrome</span><span class="headingEndMark"> — </span>Patients with Lynch syndrome, an autosomal dominant disorder that is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes, are at risk for colon cancer and a variety of extracolonic cancers, including hepatobiliary neoplasms. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Extracolonic manifestations'</a>.)</p><p class="headingAnchor" id="H3758236644"><span class="h3">BAP1 tumor predisposition syndrome</span><span class="headingEndMark"> — </span>An increased risk of cholangiocarcinoma has been reported in families that carry germline missense variants of the <em>BRCA</em>-associated protein 1 (<em>BAP1</em>) gene (the clinical phenotype is called "BAP1 tumor predisposition syndrome") [<a href="#rid87">87</a>]. In one report of 40 probands, two (5 percent) developed cholangiocarcinoma, compared with none of the 113 ungenotyped relatives. Interestingly, in The Cancer Genome Atlas (TCGA), somatic mutations in the <em>BAP1</em> gene were reported in 11 of 51 cholangiocarcinomas [<a href="#rid88">88</a>], and a putative role for <em>BAP1</em> as a tumor suppressor gene in cholangiocarcinoma has been suggested [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H3650530779"><span class="h3">Multiple biliary papillomatosis</span><span class="headingEndMark"> — </span>Multiple biliary papillomatosis is characterized by multiple adenomatous polyps of variable distribution and extent in the intrahepatic bile ducts, and repeated episodes of abdominal pain, jaundice, and acute cholangitis [<a href="#rid90">90</a>]. Biliary papillomatosis should be considered a premalignant condition and considered for resection since a high proportion of these lesions (83 percent in one study [<a href="#rid90">90</a>]) undergo malignant transformation [<a href="#rid91">91,92</a>].</p><p class="headingAnchor" id="H690341459"><span class="h3">Cystic fibrosis</span><span class="headingEndMark"> — </span>Patients with cystic fibrosis have an increased risk of biliary tract cancers. In a meta-analysis, the standardized incidence ratio was 17.87, 95% CI 8.55-37.36, and it was two- to fivefold higher in patients who had undergone lung transplantation compared with those who did not undergo transplantation [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease", section on 'Gastrointestinal cancer'</a>.)</p><p class="headingAnchor" id="H1402953963"><span class="h2">Toxic exposures</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thorotrast</strong> – A clear association exists between exposure to Thorotrast (a radiologic contrast agent banned in the 1960s for its carcinogenic properties) and subsequent cholangiocarcinoma; malignancy usually develops 30 to 35 years after exposure [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occupational exposures</strong> – An increased incidence of cholangiocarcinoma has been less strongly associated with several occupations, including the auto, rubber, chemical, and wood-finishing industries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking and alcohol</strong> – Individual studies on the association between smoking/alcohol intake and risk of cholangiocarcinoma have been conflicting. A pooled analysis of 26 prospective studies concluded that alcohol consumption was only associated with intrahepatic cholangiocarcinoma, with an increased risk for individuals consuming five or more versus zero drinks per day (HR 2.25, 95% CI 1.46-3.78) [<a href="#rid95">95</a>]. By contrast, ever, former, or current smoking was associated with an increased risk of extrahepatic bile duct and ampulla of Vater cancer, with dose-response effects for duration and intensity of smoking. Current smoking and smoking intensity were also associated with intrahepatic cholangiocarcinoma risk (for &gt;40 cigarettes per day versus never smokers, HR 2.15, 95% CI 1.15-4.0).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – Increased iron levels (both in patients with hereditary hemochromatosis and nonhemochromatosis populations) increase the risk of primary liver cancer, including cholangiocarcinoma [<a href="#rid96">96,97</a>]. (See  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H3637038478"><span class="h2">Infections</span></p><p class="headingAnchor" id="H2292382571"><span class="h3">Parasitic infection</span><span class="headingEndMark"> — </span>In Asia (particularly Thailand), infection with liver flukes of the genera Clonorchis and Opisthorchis is associated with cholangiocarcinoma of the intrahepatic bile ducts [<a href="#rid64">64,98,99</a>]. Humans are infected by consuming undercooked fish, with the adult worms inhabiting and laying eggs in the biliary system. These organisms induce a chronic inflammatory state in the proximal biliary tree, presumably leading to malignant transformation of the lining epithelium. Carcinogens that are produced by bacteria in fish and other foods, smoking, alcohol, and HBV infection might also act as cofactors [<a href="#rid47">47,100,101</a>].</p><p class="headingAnchor" id="H19"><span class="h3">HIV infection</span><span class="headingEndMark"> — </span>HIV infection was an independent risk factor for intrahepatic cholangiocarcinoma in the Medicare population in the case control study described above (aOR 6.4) [<a href="#rid28">28</a>]. However, the validity of the association is uncertain given the relatively small number of cases that were identified and the possibility that at least some of the HIV infected cases may have had coexisting, undiagnosed risk factors (such as HCV infection).</p><p class="headingAnchor" id="H86387666"><span class="h3">H. pylori infection</span><span class="headingEndMark"> — </span>Several studies report an association between biliary tract carcinoma and infection with <em>Helicobacter pylori</em> [<a href="#rid74">74,102-105</a>]. Although a cause and effect relationship has not been proven, some have suggested that <em>H. pylori</em> may be involved in the pathogenesis of biliary neoplasms through enhanced biliary cell inflammation and proliferation [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H3221774714"><span class="h2">Other factors</span></p><p class="headingAnchor" id="H2648927154"><span class="h3">Elevated blood glucose</span><span class="headingEndMark"> — </span>An association between diabetes mellitus and cancer of the biliary tract has been suggested in several case-control and cohort studies. In a meta-analysis of 15 such studies, individuals with diabetes had a significantly increased risk of cholangiocarcinoma relative to nondiabetics (summary RR 1.60, 95% CI 1.38-1.87) [<a href="#rid106">106</a>]. The risk was significantly elevated for both intrahepatic and extrahepatic cholangiocarcinomas. Whether elevated blood sugar or other diabetes-associated conditions (eg, obesity, hyperlipidemia) represent the true risk factors for cholangiocarcinoma is not clear.</p><p>An association between consumption of sweetened beverages (which raises blood glucose concentration) and extrahepatic cholangiocarcinoma was suggested in a prospective analysis of 70,832 Swedish adults enrolled in the Swedish Mammography Cohort and Cohort of Swedish Men who were free of cancer and diabetes and who completed a food frequency questionnaire at baseline [<a href="#rid107">107</a>]. Incident cases of biliary tract cancer were ascertained through linkage with the Swedish Cancer Register. With a mean follow-up of over 13 years, after adjustment for other risk factors, women and men in the highest category of combined sugar-sweetened and artificially sweetened beverage consumption had a significantly higher risk of extrahepatic cholangiocarcinoma (multivariable hazard ratio [HR] for two or more 200 mL servings per day of sweetened beverages compared with no consumption was 1.79, 95% CI 1.02-3.13). The corresponding HR for intrahepatic cholangiocarcinoma was 1.69, 95% CI 0.41-7.03.</p><p class="headingAnchor" id="H845598640"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>Obesity has been linked to an increased risk for cholangiocarcinoma, particularly intrahepatic cholangiocarcinoma [<a href="#rid68">68,108</a>].</p><p class="headingAnchor" id="H2682618236"><span class="h3">Metabolic syndrome</span><span class="headingEndMark"> — </span>A study that included 743 patients with intrahepatic cholangiocarcinoma found that the presence of metabolic syndrome (defined by the presence of three of the following: elevated waist circumference/central obesity, dyslipidemia, hypertension, or impaired fasting glucose) was a risk factor for intrahepatic cholangiocarcinoma (aOR 1.56) [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H1222795208"><span class="h3">Medications</span><span class="headingEndMark"> — </span>A few medications have been linked to an increased incidence of cholangiocarcinoma, although causality is not proven.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DPP-4 inhibitors</strong> – For adults with type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors may increase the risk of cholangiocarcinoma, although data are mixed [<a href="#rid110">110,111</a>]. In a large cohort study with over 600,000 person-years of follow-up, patients with type 2 diabetes who were treated with DPP-4 inhibitors had an increased risk of cholangiocarcinoma compared with patients receiving other antidiabetic medications (adjusted HR 1.77, 95% CI 1.04-3.01) [<a href="#rid110">110</a>]. An earlier study failed to show such an association [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/z/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral contraceptives</strong> – At least one study found that long-term use of oral contraceptives (9+ years) was associated with a significantly increased risk of intrahepatic cholangiocarcinoma (HR 1.62, 95% CI 1.03-2.55) [<a href="#rid112">112</a>]. Prior data had shown a relationship between exogenous hormone use and an increased risk of all primary liver cancers [<a href="#rid113">113</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h1">HISTOLOGY AND IMMUNOHISTOCHEMISTRY</span><span class="headingEndMark"> — </span>Cholangiocarcinomas can be classified according to their location along the biliary tree  (<a class="graphic graphic_figure graphicRef52489" href="/z/d/graphic/52489.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef75886" href="/z/d/graphic/75886.html" rel="external">figure 2</a>). The majority (75 percent in one report [<a href="#rid31">31</a>]) are found in the upper one-third of the biliary tract, and two-thirds involve the bifurcation of the common hepatic duct (Klatskin tumors). Intrahepatic nonperihilar tumors (ie, peripheral cholangiocarcinomas) are the least common, accounting for fewer than 10 percent of cases in most series. Up to 7 percent of tumors are multicentric at the time of diagnosis [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Cholangiocarcinoma</span><span class="headingEndMark"> — </span>The majority of cholangiocarcinomas (&gt;90 percent) are adenocarcinomas, with squamous cell carcinoma being responsible for most of the remaining cases; adenosquamous cancers are rare. They are graded as well, moderately, or poorly differentiated. Histologic findings and immunohistochemical stains that can assist in the differential diagnosis of cholangiocarcinoma from other malignancies, particularly those that arise in liver, are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Cholangiocarcinoma'</a>.)</p><p>Intrahepatic adenocarcinomas are divided into large duct type  (<a class="graphic graphic_picture graphicRef122187" href="/z/d/graphic/122187.html" rel="external">picture 4</a>) and small duct type  (<a class="graphic graphic_picture graphicRef122188" href="/z/d/graphic/122188.html" rel="external">picture 5</a>) [<a href="#rid115">115</a>]. Morphologically, both intrahepatic and extrahepatic biliary adenocarcinomas can be sclerosing, nodular, or papillary [<a href="#rid115">115,116</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Sclerosing</span><span class="headingEndMark"> — </span>Sclerosing (scirrhous) tumors are characterized by an intense desmoplastic reaction. The extensive fibrosis makes preoperative diagnosis by biopsy and cytology more difficult than for other tumors (see  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma"</a>). These tumors also tend to invade the bile duct wall early and, as a result, are associated with low resectability and cure rates. Intraductal spread may mimic primary sclerosing cholangitis (PSC) on cholangiographic studies, complicating the radiographic diagnosis. Unfortunately, most cholangiocarcinomas are of this type. In one report, 94 percent of 194 perihilar tumors were sclerotic adenocarcinomas, as were 79 of 80 distal tumors and all nine intrahepatic cholangiocarcinomas [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Nodular</span><span class="headingEndMark"> — </span>Nodular cholangiocarcinomas present as a constricting annular lesion of the bile duct. These are highly invasive tumors, and most patients have advanced disease at the time of diagnosis; thus, the resectability and cure rates are very low.</p><p class="headingAnchor" id="H24"><span class="h3">Papillary</span><span class="headingEndMark"> — </span>Papillary tumors are the rarest form of cholangiocarcinoma. These usually present as bulky masses in the common bile duct lumen, which cause biliary obstruction early in the course of the disease. For this reason, they have the highest resectability and cure rates [<a href="#rid117">117,118</a>].</p><p>Characteristics that are common to all three tumor types include slow growth, a high rate of local invasion, mucin production, and a tendency to invade perineural sheaths and spread along nerves. By contrast, distant metastases are distinctly uncommon in cholangiocarcinoma.</p><p>Most intrahepatic cholangiocarcinomas are adenocarcinomas with variable desmoplastic reaction, although there are several special or unusual histological features depending on the site of origin [<a href="#rid119">119</a>]. At the large intrahepatic bile ducts, papillary growth and periductal infiltration is typical, while tumors arising from ductules share a similar phenotype with hepatocellular carcinoma (HCC). In addition to invasive cancer, intrahepatic cholangiocarcinomas that arise in the setting of chronic biliary disease (eg, hepatolithiasis) are characterized by precancerous lesions including biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile ducts. (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Biliary intraepithelial neoplasia'</a> and  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Intraductal papillary neoplasm of bile duct'</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>There are no known proteins that are differentially expressed by normal and malignant biliary epithelium and, therefore, no pathognomonic immunohistochemical test that can be used to confirm the cell type of origin. However, positive results of several types of immunohistochemical staining may be used to support a diagnosis of malignant biliary epithelium. In particular, cytokeratin-7 (CK7) positivity is consistent with biliary tract origin  (<a class="graphic graphic_table graphicRef58475" href="/z/d/graphic/58475.html" rel="external">table 5</a>). However, metastatic cancers of the lung and breast are also CK7 positive, and the diagnosis of a cholangiocarcinoma is frequently a diagnosis of exclusion. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Histology and immunohistochemistry'</a>.) </p><p class="headingAnchor" id="H646656"><span class="h2">Combined hepatocellular-cholangiocarcinoma</span><span class="headingEndMark"> — </span>Combined hepatocellular-cholangiocarcinoma, also referred to as primary liver carcinoma with biphenotypic differentiation or hepatocholangiocarcinoma, is now acknowledged as a distinct subtype of cholangiocarcinoma [<a href="#rid120">120-122</a>]. These tumors consist of intimately admixed elements of both HCC and cholangiocarcinoma. They are distinguished from separate HCC and cholangiocarcinomas arising in the same liver lobe (which may be separated or intermixed "collision" tumors). (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Combined hepatocellular-cholangiocarcinoma'</a>.) </p><p>These tumors are staged as intrahepatic cholangiocarcinomas and not HCCs. (See <a class="local">'TNM staging classifications'</a> above.)</p><p>The cell of origin is debated, but the available evidence supports the view that combined hepatocellular-cholangiocarcinoma arise from a common hepatic stem cell. It is generally accepted that adult hepatic stem cells are capable of biliary or hepatocyte differentiation [<a href="#rid123">123,124</a>]. Further, investigators have shown that in at least one case, combined hepatocellular-cholangiocarcinoma was derived from a single clone, and primary cell lines derived from resected combined tumors can be induced to differentiate to the characteristics of HCC and cholangiocarcinoma under different growth conditions [<a href="#rid125">125,126</a>]. Finally, molecular studies suggest that tumors that exhibit both biliary and hepatocyte differentiation exhibit stem cell/progenitor features, a down-regulation of the hepatocyte differentiation program, and a commitment to the biliary lineage [<a href="#rid127">127</a>].</p><p>Combined hepatocellular-cholangiocarcinomas have distinct imaging characteristics, and they are typically treated surgically. Although multimodality therapy is often employed [<a href="#rid128">128,129</a>], its benefit is unproven. The prognosis is thought to be intermediate between that of pure HCC and intrahepatic cholangiocarcinoma [<a href="#rid129">129-133</a>]. Patients with advanced disease should be treated according to the principles established for advanced cholangiocarcinoma [<a href="#rid134">134</a>]. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma", section on 'MRI and MRCP'</a> and  <a class="medical medical_review" href="/z/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma"</a>.)</p><p class="headingAnchor" id="H646983"><span class="h1">MOLECULAR PATHOGENESIS</span><span class="headingEndMark"> — </span>A detailed discussion of the molecular pathogenesis of cholangiocarcinomas is beyond the scope of this discussion and is well-reviewed elsewhere [<a href="#rid135">135,136</a>]. What follows is a brief overview of the salient points.</p><p>There are two precursors to cholangiocarcinoma: intraductal papillary mucinous neoplasm of the bile duct and the much more common biliary intraepithelial neoplasia. Biliary intraepithelial neoplasia is graded based on the extent of cellular atypia, mirroring the spectrum of precursor lesions for pancreatic cancer [<a href="#rid137">137</a>]. Intraductal papillary mucinous neoplasm of the bile duct is a macroscopic lesion similar to its pancreatic counterpart [<a href="#rid138">138</a>]. (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Intraductal papillary neoplasm of bile duct'</a> and  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Biliary intraepithelial neoplasia'</a> and  <a class="medical medical_review" href="/z/d/html/2510.html" rel="external">"Pathology of exocrine pancreatic neoplasms", section on 'Pancreatic intraepithelial neoplasia'</a> and  <a class="medical medical_review" href="/z/d/html/2510.html" rel="external">"Pathology of exocrine pancreatic neoplasms", section on 'Intraductal papillary mucinous neoplasms'</a>.)</p><p>Conversion from normal to malignant bile epithelium through one of these precursor lesions probably requires a stepwise accumulation of successive genetic abnormalities, similar to the sequence of events that underlies colorectal carcinogenesis [<a href="#rid135">135,139,140</a>]. However, the level of understanding of the molecular pathogenesis of cholangiocarcinoma is significantly less than that of other gastrointestinal cancers. Molecularly, the precursors of carcinoma remain poorly characterized, although they appear to harbor mutations in p53 and loss of <em>SMAD4</em> [<a href="#rid141">141,142</a>]. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer"</a>.)</p><p>A variety of molecular defects involving both oncogenes (<em>RAS</em>, <em>ERBB2</em>, <em>BRAF,</em> <em>EGFR</em>, <em>PIK3CA</em>, <em>CTNNB1</em>) and tumor suppressor genes (eg, p53, <em>SMAD4</em>, <em>CDKN2A</em>) have been described in specimens of invasive biliary tract tumors. As an example, approximately one-third of tumors overexpress p53 (implying the presence of mutations in this tumor suppressor gene), while abnormal expression of KRAS is found in 45 to 54 percent of intrahepatic cholangiocarcinomas and 10 to 15 percent of extrahepatic cholangiocarcinomas [<a href="#rid135">135</a>]. These genetic alterations seem to be associated with a more aggressive tumor phenotype [<a href="#rid143">143,144</a>].</p><p>The contribution of these genetic changes to cholangiocarcinoma genesis and their relationship to chronic inflammation, ethnic background, and carcinogen exposure remain uncertain (see <a class="local">'Risk factors'</a> above). At least some data suggest that p16INK4a promoter point mutations contribute to initiation and progression of cholangiocarcinoma in the setting of primary sclerosing cholangitis (PSC) [<a href="#rid145">145,146</a>]. </p><p>Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in 25 percent of intrahepatic cholangiocarcinomas and not extrahepatic cholangiocarcinomas or gallbladder carcinomas [<a href="#rid147">147</a>]. In this study, the frequency of <em>IDH1</em> and <em>IDH2</em> gene mutations was greater than the combined frequency of activating mutations in other genes (<em>AKT1</em>, <em>KRAS</em>, <em>NRAS</em>, and <em>BRAF</em>) in intrahepatic cholangiocarcinomas. This suggests potential for targeting this pathway in intrahepatic cholangiocarcinoma.</p><p>Although current knowledge is limited, it is hoped that advances in the understanding of the genetic pathways that contribute to the development of cholangiocarcinomas will identify driver mutations that can be successfully targeted for therapeutic benefit [<a href="#rid148">148</a>]. However, at present, there are no molecular markers that are currently used for prognosis or selecting treatment.</p><p class="headingAnchor" id="H25322780"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The term cholangiocarcinoma refers to bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of the gallbladder or ampulla of Vater. Cancers arising in the perihilar region are further classified according to their patterns of involvement of the hepatic ducts (the Bismuth-Corlette classification)  (<a class="graphic graphic_figure graphicRef75886" href="/z/d/graphic/75886.html" rel="external">figure 2</a>). (See <a class="local">'Bismuth-Corlette classification for perihilar tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The Tumor, Node, Metastasis (TNM) staging classification from the joint American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) includes separate staging systems for intrahepatic, perihilar, and distal bile duct tumors, which differ in their definitions of primary tumor stage and their prognostic stage groupings. (See <a class="local">'Anatomy, tumor classification, and staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The incidence of biliary tract cancer increases with age; the typical patient with cholangiocarcinoma is between 50 and 70 years old. The incidence rates of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma have been rising over the past two to four decades in most countries. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – A number of risk factors for cholangiocarcinoma have been recognized, although a specific risk factor cannot be identified for many patients. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the United States and Europe, the main risk factors are primary sclerosing cholangitis and choledochal cysts (fibropolycystic liver disease). (See <a class="local">'Primary sclerosing cholangitis'</a> above and <a class="local">'Fibropolycystic liver disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Southeast Asia has a very high incidence of cholangiocarcinoma that is due to a high prevalence of hepatobiliary flukes. (See <a class="local">'Parasitic infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is a clear and strong association between chronic intrahepatic stone disease (hepatolithiasis, also called recurrent pyogenic cholangitis) and cholangiocarcinoma. (See <a class="local">'Cholelithiasis, cholecystitis, and hepatolithiasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic liver disease (cirrhosis and viral infection) is a risk factor, especially for intrahepatic cholangiocarcinoma. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic disorders</strong> – At least two genetic disorders are associated with an increased risk of cholangiocarcinoma: Lynch syndrome (hereditary nonpolyposis colorectal cancer) and a rare inherited disorder called multiple biliary papillomatosis. (See <a class="local">'Genetic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – The majority of cholangiocarcinomas (&gt;90 percent) are adenocarcinomas, with squamous cell carcinoma being responsible for most of the remaining cases. Intrahepatic adenocarcinomas can be of the small duct or large duct type. Morphologically, cholangiocarcinomas may present as one of three types: nodular, sclerosing, or papillary. (See <a class="local">'Cholangiocarcinoma'</a> above.)</p><p></p><p class="bulletIndent1">Combined hepatocellular-cholangiocarcinoma, also referred to as primary liver carcinoma with biphenotypic differentiation, is now acknowledged as a distinct rare subtype of cholangiocarcinoma. Prognosis is intermediate between that of hepatocellular cancer and intrahepatic cholangiocarcinoma. (See <a class="local">'Combined hepatocellular-cholangiocarcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular pathogenesis</strong> – A variety of molecular defects involving both oncogenes and tumor suppressor genes have been described in specimens of invasive biliary tract tumors. Conversion from normal to malignant bile epithelium through one of these precursor lesions probably requires a stepwise accumulation of successive genetic abnormalities. However, the level of understanding of the molecular pathogenesis of cholangiocarcinoma is significantly less than that of other gastrointestinal cancers. (See <a class="local">'Molecular pathogenesis'</a> above.)</p><p></p><p class="headingAnchor" id="H1611464114"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Nezam H Afdhal, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Nagorney DM, Pawlik TM, Chun YS, et al. Perihilar bile ducts. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.311.</li><li><a class="nounderline abstract_t">DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755.</a></li><li><a class="nounderline abstract_t">Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31.</a></li><li class="breakAll">Krasinskas A, Pawlik TM, Mino-Kenudson M, Vauthey J-N. Distal bile duct. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.317.</li><li class="breakAll">Aloia T, Pawlik TM, Taouli B, et al. Intrahepatic bile ducts. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.295.</li><li><a class="nounderline abstract_t">Hong SM, Pawlik TM, Cho H, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009; 146:250.</a></li><li><a class="nounderline abstract_t">Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol 2017; 115:696.</a></li><li><a class="nounderline abstract_t">Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53:1363.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14:109.</a></li><li><a class="nounderline abstract_t">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12.</a></li><li><a class="nounderline abstract_t">Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353.</a></li><li><a class="nounderline abstract_t">Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40:472.</a></li><li><a class="nounderline abstract_t">Patel N, Benipal B. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus 2019; 11:e3962.</a></li><li><a class="nounderline abstract_t">Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13:261.</a></li><li class="breakAll">Cancer Today: Data visualization tools for exploring the global cancer burden in 2020 https://gco.iarc.fr/today/home (Accessed on August 14, 2023).</li><li><a class="nounderline abstract_t">Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet 2021; 397:428.</a></li><li><a class="nounderline abstract_t">Ouyang G, Liu Q, Wu Y, et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017. Cancer 2021; 127:2238.</a></li><li><a class="nounderline abstract_t">Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99:895.</a></li><li><a class="nounderline abstract_t">West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751.</a></li><li><a class="nounderline abstract_t">Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park) 2004; 18:889.</a></li><li><a class="nounderline abstract_t">Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37:806.</a></li><li><a class="nounderline abstract_t">Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.</a></li><li><a class="nounderline abstract_t">Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98:873.</a></li><li><a class="nounderline abstract_t">Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 2020; 126:2666.</a></li><li><a class="nounderline abstract_t">Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 2016; 21:594.</a></li><li><a class="nounderline abstract_t">Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56:848.</a></li><li><a class="nounderline abstract_t">Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000; 19:156.</a></li><li><a class="nounderline abstract_t">Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128:620.</a></li><li><a class="nounderline abstract_t">Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer 2019; 125:1489.</a></li><li><a class="nounderline abstract_t">Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610.</a></li><li><a class="nounderline abstract_t">Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70:1498.</a></li><li><a class="nounderline abstract_t">Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10 Suppl 4:308.</a></li><li><a class="nounderline abstract_t">Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol 2020; 72:95.</a></li><li><a class="nounderline abstract_t">Tung BY, Brentnall T, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with primary sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.</a></li><li><a class="nounderline abstract_t">Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321.</a></li><li><a class="nounderline abstract_t">Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.</a></li><li><a class="nounderline abstract_t">Bergquist A, Glaumann H, Persson B, Broomé U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27:311.</a></li><li><a class="nounderline abstract_t">de Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? Hepatology 2000; 31:247.</a></li><li><a class="nounderline abstract_t">Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523.</a></li><li><a class="nounderline abstract_t">Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50:158.</a></li><li><a class="nounderline abstract_t">Chapman MH, Webster GJ, Bannoo S, et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012; 24:1051.</a></li><li><a class="nounderline abstract_t">Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.</a></li><li><a class="nounderline abstract_t">LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899.</a></li><li><a class="nounderline abstract_t">Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58:2045.</a></li><li><a class="nounderline abstract_t">Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31:7.</a></li><li><a class="nounderline abstract_t">Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008; 47:90.</a></li><li><a class="nounderline abstract_t">Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366:1303.</a></li><li><a class="nounderline abstract_t">Scott J, Shousha S, Thomas HC, Sherlock S. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol 1980; 73:113.</a></li><li><a class="nounderline abstract_t">Lipsett PA, Pitt HA, Colombani PM, et al. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994; 220:644.</a></li><li><a class="nounderline abstract_t">Dayton MT, Longmire WP Jr, Tompkins RK. Caroli's Disease: a premalignant condition? Am J Surg 1983; 145:41.</a></li><li><a class="nounderline abstract_t">Hsing AW, Gao YT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007; 97:1577.</a></li><li><a class="nounderline abstract_t">Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol 2007; 19:623.</a></li><li><a class="nounderline abstract_t">Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120:638.</a></li><li><a class="nounderline abstract_t">Lee PC, Hu YW, Hu LY, et al. Risk of cancer in patients with cholecystitis: a nationwide population-based study. Am J Med 2015; 128:185.</a></li><li><a class="nounderline abstract_t">Chijiiwa K, Yamashita H, Yoshida J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995; 130:194.</a></li><li><a class="nounderline abstract_t">Lee CC, Wu CY, Chen GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol 2002; 17:1015.</a></li><li><a class="nounderline abstract_t">Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 1999; 14:1144.</a></li><li><a class="nounderline abstract_t">Su CH, Shyr YM, Lui WY, P'Eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997; 84:969.</a></li><li><a class="nounderline abstract_t">Kinami Y, Noto H, Miyazaki I, et al. A study of hepatolithiasis associated with cholangiocarcinoma. Acta Hepatol Jpn 1978; 19:573.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Tsuchiya R, Ito I, et al. A study of cholangiocarcinoma coexisting with hepatolithiasis. Jpn J Gastroenterol Surg 1984; 17:601.</a></li><li><a class="nounderline abstract_t">Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977; 39:232.</a></li><li><a class="nounderline abstract_t">Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12:959.</a></li><li><a class="nounderline abstract_t">Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003; 50:8.</a></li><li><a class="nounderline abstract_t">Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25:933.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88:2471.</a></li><li><a class="nounderline abstract_t">Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28:921.</a></li><li><a class="nounderline abstract_t">Nagaoka T, Ohkawa S, Ito Y, et al. [A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography]. Nihon Shokakibyo Gakkai Zasshi 1991; 88:1369.</a></li><li><a class="nounderline abstract_t">Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1221.</a></li><li><a class="nounderline abstract_t">Hsing AW, Zhang M, Rashid A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122:1849.</a></li><li><a class="nounderline abstract_t">Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95:592.</a></li><li><a class="nounderline abstract_t">Liu XF, Zou SQ, Qiu FZ. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int 2003; 2:285.</a></li><li><a class="nounderline abstract_t">Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17:1049.</a></li><li><a class="nounderline abstract_t">Lu H, Ye MQ, Thung SN, et al. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J (Engl) 2000; 113:1138.</a></li><li><a class="nounderline abstract_t">Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One 2013; 8:e69981.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Xu J, Harada K, et al. Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases. Pathol Int 2011; 61:298.</a></li><li><a class="nounderline abstract_t">Suriawinata A, Thung SN. Hepatitis C virus and malignancy. Hepatol Res 2007; 37:397.</a></li><li><a class="nounderline abstract_t">El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49:116.</a></li><li><a class="nounderline abstract_t">Mahale P, Torres HA, Kramer JR, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study. Cancer 2017; 123:1202.</a></li><li><a class="nounderline abstract_t">Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100:1765.</a></li><li><a class="nounderline abstract_t">Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol 2011; 18:1258.</a></li><li><a class="nounderline abstract_t">Kinoshita M, Kubo S, Tanaka S, et al. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study. J Surg Oncol 2016; 113:779.</a></li><li><a class="nounderline abstract_t">Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012; 56:1352.</a></li><li class="breakAll">Nakanumna Y, Basturk O, Esposito I, et al. Intraductal papillary neoplasm of the bile ducts. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.279.</li><li><a class="nounderline abstract_t">Schlitter AM, Jang KT, Klöppel G, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol 2015; 28:1249.</a></li><li><a class="nounderline abstract_t">Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Surg Oncol Clin N Am 2009; 18:215.</a></li><li class="breakAll">Basturk O. Aishima S, Esposito I. Biliary intraepithelial neoplasia. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.273.</li><li><a class="nounderline abstract_t">Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst 2018; 110:1328.</a></li><li><a class="nounderline abstract_t">Deng M, Brägelmann J, Schultze JL, Perner S. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics 2016; 17:72.</a></li><li><a class="nounderline abstract_t">Chen XX, Yin Y, Cheng JW, et al. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death Dis 2018; 9:1036.</a></li><li><a class="nounderline abstract_t">Lee SS, Kim MH, Lee SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004; 100:783.</a></li><li><a class="nounderline abstract_t">Taguchi J, Yasunaga M, Kojiro M, et al. Intrahepatic and extrahepatic biliary papillomatosis. Arch Pathol Lab Med 1993; 117:944.</a></li><li><a class="nounderline abstract_t">Yeung YP, AhChong K, Chung CK, Chun AY. Biliary papillomatosis: report of seven cases and review of English literature. J Hepatobiliary Pancreat Surg 2003; 10:390.</a></li><li><a class="nounderline abstract_t">Yamada A, Komaki Y, Komaki F, et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol 2018; 19:758.</a></li><li><a class="nounderline abstract_t">Sahani D, Prasad SR, Tannabe KK, et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging 2003; 28:72.</a></li><li><a class="nounderline abstract_t">McGee EE, Jackson SS, Petrick JL, et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J Natl Cancer Inst 2019; 111:1263.</a></li><li><a class="nounderline abstract_t">Tran KT, Coleman HG, McCain RS, Cardwell CR. Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis. Nutr Cancer 2019; 71:1365.</a></li><li><a class="nounderline abstract_t">Atkins JL, Pilling LC, Masoli JAH, et al. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA 2020; 324:2048.</a></li><li><a class="nounderline abstract_t">Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg 1996; 83:1062.</a></li><li><a class="nounderline abstract_t">Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002; 89:962.</a></li><li><a class="nounderline abstract_t">Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005; 117:854.</a></li><li><a class="nounderline abstract_t">Zhang GW, Lin JH, Qian JP, Zhou J. Identification of risk and prognostic factors for patients with clonorchiasis-associated intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014; 21:3628.</a></li><li><a class="nounderline abstract_t">Bulajic M, Maisonneuve P, Schneider-Brachert W, et al. Helicobacter pylori and the risk of benign and malignant biliary tract disease. Cancer 2002; 95:1946.</a></li><li><a class="nounderline abstract_t">Pandey M, Shukla M. Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers. Surg Oncol 2009; 18:51.</a></li><li><a class="nounderline abstract_t">Boonyanugomol W, Chomvarin C, Sripa B, et al. Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. HPB (Oxford) 2012; 14:177.</a></li><li><a class="nounderline abstract_t">Murphy G, Michel A, Taylor PR, et al. Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study. Hepatology 2014; 60:1963.</a></li><li><a class="nounderline abstract_t">Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21:24.</a></li><li><a class="nounderline abstract_t">Larsson SC, Giovannucci EL, Wolk A. Sweetened Beverage Consumption and Risk of Biliary Tract and Gallbladder Cancer in a Prospective Study. J Natl Cancer Inst 2016; 108.</a></li><li><a class="nounderline abstract_t">Grainge MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100:178.</a></li><li><a class="nounderline abstract_t">Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54:463.</a></li><li><a class="nounderline abstract_t">Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018; 363:k4880.</a></li><li><a class="nounderline abstract_t">Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab 2016; 18:186.</a></li><li><a class="nounderline abstract_t">Petrick JL, McMenamin ÚC, Zhang X, et al. Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank. Br J Cancer 2020; 123:316.</a></li><li><a class="nounderline abstract_t">McGlynn KA, Sahasrabuddhe VV, Campbell PT, et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer 2015; 112:1266.</a></li><li><a class="nounderline abstract_t">Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463.</a></li><li class="breakAll">Nakanuma Y, Klimstra DS, Komuta M, Zen Y. Intrahepatic cholangiocarcinoma. In: WHO Classification of Tumours" Digestive system tumors, 5th ed, WHO Classification of Tumours Editorial Board. (Ed), International Agency for Research on Cancer, Lyon 2019. p.254.</li><li class="breakAll">Roa JC, Adsay NV, Arola J, et al. Carcinoma of the extrahepatic bile ducts.. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.289.</li><li><a class="nounderline abstract_t">Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241:703.</a></li><li><a class="nounderline abstract_t">Martin RC, Klimstra DS, Schwartz L, et al. Hepatic intraductal oncocytic papillary carcinoma. Cancer 2002; 95:2180.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Harada K, Ishikawa A, et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10:265.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010; 2:419.</a></li><li><a class="nounderline abstract_t">Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37:496.</a></li><li class="breakAll">Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma. In: WHO Classificatrion of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.260.</li><li><a class="nounderline abstract_t">Alison MR. Liver stem cells: implications for hepatocarcinogenesis. Stem Cell Rev 2005; 1:253.</a></li><li><a class="nounderline abstract_t">Wu XZ, Chen D. Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol 2006; 21:1093.</a></li><li><a class="nounderline abstract_t">Yano H, Iemura A, Haramaki M, et al. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol 1996; 24:413.</a></li><li><a class="nounderline abstract_t">Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol 2000; 31:1011.</a></li><li><a class="nounderline abstract_t">Coulouarn C, Cavard C, Rubbia-Brandt L, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis 2012; 33:1791.</a></li><li><a class="nounderline abstract_t">Lee CH, Hsieh SY, Chang CJ, Lin YJ. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013; 28:122.</a></li><li><a class="nounderline abstract_t">Spolverato G, Bagante F, Tsilimigras D, et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis. J Surg Oncol 2019; 119:278.</a></li><li><a class="nounderline abstract_t">Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008; 62:1271.</a></li><li><a class="nounderline abstract_t">Yap AQ, Chen CL, Yong CC, et al. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. Surg Oncol 2013; 22:55.</a></li><li><a class="nounderline abstract_t">Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19:2869.</a></li><li><a class="nounderline abstract_t">Garancini M, Goffredo P, Pagni F, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014; 20:952.</a></li><li><a class="nounderline abstract_t">Salimon M, Prieux-Klotz C, Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer 2018; 118:325.</a></li><li><a class="nounderline abstract_t">Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28:3531.</a></li><li><a class="nounderline abstract_t">Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech 2013; 6:281.</a></li><li><a class="nounderline abstract_t">Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20:701.</a></li><li><a class="nounderline abstract_t">Klöppel G, Kosmahl M. Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol 2006; 44:249.</a></li><li><a class="nounderline abstract_t">Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383:2168.</a></li><li><a class="nounderline abstract_t">Schlitter AM, Born D, Bettstetter M, et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 2014; 27:73.</a></li><li><a class="nounderline abstract_t">Nakanishi Y, Zen Y, Kondo S, et al. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 2008; 39:1153.</a></li><li><a class="nounderline abstract_t">Hoang MP, Murakata LA, Katabi N, et al. Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 2002; 15:1251.</a></li><li><a class="nounderline abstract_t">Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49:604.</a></li><li><a class="nounderline abstract_t">Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24:139.</a></li><li><a class="nounderline abstract_t">Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123:1090.</a></li><li><a class="nounderline abstract_t">Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47:721.</a></li><li><a class="nounderline abstract_t">Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17:72.</a></li><li><a class="nounderline abstract_t">Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142:1021.</a></li></ol></div><div id="topicVersionRevision">Topic 663 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nagorney DM, Pawlik TM, Chun YS, et al. Perihilar bile ducts. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.311.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457168" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309988" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management strategies in resection for hilar cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309988" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management strategies in resection for hilar cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309988" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management strategies in resection for hilar cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628081" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28194791" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21480336" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New staging system and a registry for perihilar cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8047893" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recent advances in the management of cholangiocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38230766" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cancer statistics, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391522" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123362" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30956914" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095655" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095655" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33516341" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33748947" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551150" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16736026" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15255172" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12445422" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Changing international trends in mortality rates for liver, biliary and pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991810" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Worldwide trends in mortality from biliary tract malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788161" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32129902" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27000463" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22173164" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126380" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cholangiocarcinoma of the extrahepatic bile ducts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15765398" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30645774" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707097" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516001" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10436847" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for biliary tract carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536748" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnosis and prevalence of ulcerative colitis in patients with primary sclerosing cholangitis (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867174" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7877651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462625" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613754" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056096" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19012991" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High lifetime risk of cancer in primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22653260" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845927" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cholangiocarcinoma complicating primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366557" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Current concepts. Primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775876" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613720" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18023027" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214602" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6249119" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979612" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Choledochal cyst disease. A changing pattern of presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6295196" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Caroli's Disease: a premalignant condition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000509" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gallstones and the risk of biliary tract cancer: a population-based study in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17625430" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109384" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447627" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk of cancer in patients with cholecystitis: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848091" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Current management and long-term prognosis of hepatolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167124" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634149" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240138" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hepatolithiasis associated with cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A study of hepatolithiasis associated with cholangiocarcinoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A study of cholangiocarcinoma coexisting with hepatolithiasis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/64293" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808716" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629979" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921477" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861422" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9755226" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1653864" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689296" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076042" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15245596" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599986" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201863" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776153" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23894567" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501296" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437526" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hepatitis C virus and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19085911" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117886" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436294" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21207172" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26996383" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504729" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504729" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111977" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306808" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306808" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517737" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26852330" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Web-TCGA: an online platform for integrated analysis of molecular cancer data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305612" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14770435" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinicopathologic review of 58 patients with biliary papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8368911" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Intrahepatic and extrahepatic biliary papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598142" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Biliary papillomatosis: report of seven cases and review of English literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706374" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12483389" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Thorotrast-induced cholangiocarcinoma: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31127946" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31044614" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33231665" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8869303" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cholangiocarcinoma in patients with opisthorchiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153620" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Liver fluke-associated cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957169" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781504" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Identification of risk and prognostic factors for patients with clonorchiasis-associated intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12404289" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Helicobacter pylori and the risk of benign and malignant biliary tract disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715780" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321036" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797247" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857525" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27281756" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Sweetened Beverage Consumption and Risk of Biliary Tract and Gallbladder Cancer in a Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018260" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21538440" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30518618" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443993" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32376888" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742475" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857851" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857851" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857851" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15849506" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412172" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Hepatic intraductal oncocytic papillary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598145" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Anatomic and molecular pathology of intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191517" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388123" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388123" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142862" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Liver stem cells: implications for hepatocarcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824058" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Origin of hepatocellular carcinoma: role of stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738727" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014564" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Genetic classification of combined hepatocellular-cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696594" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβsignaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034166" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30554420" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284443" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Management of combined hepatocellular and cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102615" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451237" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777610" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29169182" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547994" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Genetics of biliary tract cancers and emerging targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520144" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431410" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360969" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24581682" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828315" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495210" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12481004" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063950" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15192787" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Serum and bile markers for cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360471" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034592" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180306" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178589" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
